KENNEWICK, Wash., Aug. 2, 2007 (PRIME NEWSWIRE) -- Advanced Medical Isotopes Corporation (Pink Sheets:ADMD) has initiated shipments to leading universities and several international hospitals of Oxygen-18, a key ingredient for the production of Fluorine-18. The increasing usage of Fluorine-18 is essential to the expanding utilization of the development of positron emission tomography (PET). The growing usage of PET affords the ability to evaluate the metabolic and functional activity of cells, affording great promise for the diagnosis of many major diseases, including oncologic imaging for a variety of cancers, brain tumors, heart disease and Alzheimers.
Advanced Medical Isotopes recently concluded the purchase of the Life Sciences Division from Isonics and is continuing with the same source of quality supply as previously shipped.
"We anticipate expanding our presence in the marketplace and further penetrating our potential customer base both domestically as well as internationally while maintaining the delivery of quality product as well as quality servicing of those accounts," stated William J. Stokes, CEO.
About AMIC
Advanced Medical Isotopes Corporation is engaged in the development of advanced production systems and processes for bringing previously unavailable medical isotopes to the marketplace and advancing systems for local product production. The field of nuclear medicine has routinely utilized radioisotopes in the diagnosis of disease while new processes are being pioneered for the targeted treatment of diseases such as cancer in preference to surgical techniques. Advanced Medical Isotopes Corporation products support the accessibility to these less invasive therapeutic processes by advancing systems for lower cost production and improving supply availability of medical isotopes to hospitals and clinical treatment centers. For more information, please visit www.advancedmedicalisotopes.com.
Forward-Looking Statements
Except for historical information contained herein, the matters set forth in this press release, such as statements relating to the company's ability to drive technological developments and the acceptance and timing of product introductions, are forward-looking statements that are subject to risks and uncertainties, including but not limited to, timely development and acceptance of new products, the impact of competitive products and pricing, the timely development and release of products by suppliers, and other risks.